How Is The Market Feeling About Intra-Cellular Therapies?
Portfolio Pulse from Benzinga Insights
Intra-Cellular Therapies (NYSE:ITCI) has seen a 4.8% increase in short percent of float since its last report, with 3.47 million shares sold short, representing 4.15% of its available trading shares. This indicates a bearish market sentiment, although it's noted that an increase in short interest can sometimes be bullish. The company's short interest is above its peer group average of 3.98%.
April 19, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Intra-Cellular Therapies has experienced an increase in short interest, indicating a bearish sentiment among investors but also suggesting potential bullish outcomes.
The increase in short interest for Intra-Cellular Therapies suggests a bearish sentiment in the short term. However, high short interest can sometimes lead to a bullish scenario through a short squeeze if the stock price starts to rise and short sellers rush to cover their positions. The impact on the stock price in the short term is uncertain, hence the neutral score.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 90